✅ New API: 6000+ US Stock Options End-of-Day Data with 40+ fields. Learn more

Halozyme Therapeutics Inc (HALO NASDAQ) stock market data APIs

$77.009 0.48(0.6%)
as of September 15, 2025
Try our APIs with free plan!

Halozyme Therapeutics Inc Financial Data Overview

Price chart is built with Anychart
OpenFigi: BBG000CZ**** The data is available with plans that include the Fundamentals API. Check our pricing page for details. CIK: 000115**** The data is available with plans that include the Fundamentals API. Check our pricing page for details.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Prev. Close 77.009
Open 77.4904
High 77.4904
Low 75.2195
52 wk Range 42.01-77.6
Market Cap 8 995 M
P/E Ratio 17.5876
Shares Outstanding 117 M
Revenue 1 179 M
EPS 1.33
Beta 1.195

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


ETFs with Halozyme Therapeutics Inc (top by weight)

Ticker
100-day Price Change
Weight
FBT.US First Trust NYSE Arca Biotechnology Index Fund
10.77 (6.54%)
4.30
ROYL.AU Betashares Global Royalties ETF
1.06 (9.09%)
4.30
FFLS.US Northern Lights Fund Trust II
0.72 (2.87%)
3.36
XBI.US SPDR® S&P Biotech ETF
9.18 (10.89%)
3.17
XBI.MX SPDR Series Trust - SPDR S&P Biotech ETF
206.92 (13.6%)
3.16
CURE.AU Global X S&P Biotech ETF
4.02 (9.25%)
3.15
ETLI.XETRA L&G Pharma Breakthrough UCITS ETF
0.88 (9.19%)
2.99

* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Halozyme Therapeutics Inc data using free add-ons & libraries


Get Halozyme Therapeutics Inc Fundamental Data

Halozyme Therapeutics Inc Fundamental data includes:

  • Net Revenue: 1 179 M
  • EBITDA: 759 M
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Halozyme Therapeutics Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2025-08-05
  • EPS/Forecast: 1.03
GET THE PACKAGE

Get Halozyme Therapeutics Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Halozyme Therapeutics Inc News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat